Canaccord analyst Gary Newman initiates coverage on Eton Pharmaceuticals (NASDAQ: ETON) with a Buy rating and a price target of $60.00.

For an analyst ratings summary and ratings history on Eton Pharmaceuticals click here. For more ratings news on Eton Pharmaceuticals click here.

Shares of Eton Pharmaceuticals closed at $38.50 yesterday.